Blood: Promoting red blood cell production joint iron restriction seislus significantly improved anemia of beta-thalassemia

Moderate thalassemia is a disease characterized by red blood cell production ineffective (IE), anemia, spleen enlargement, and systemic iron overloadResearchers are exploring new treatments based on reduced iron absorption, such as the use of ferritin activators: Tmprs6-antonyonucleotides (ASO), etc.), or increasered red blood cell production, such as the ability to promote erythropoietin (EPO) or regulate the ability of the ferritin receptor 2 (Tfr2) to control RBC synthesistargeting Tmprss6 mRNA with Tmprss6-ASO has been shown to increase induced iron limits effectively increase IE and spleen swellingBut Casu and others speculate that combination therapy may be more effective than monotherapyTherefore, Casu et alused Tmprs6-ASO in combination with EPO or knocked out a single Tfr2 allele in the bone marrow of animals affected by beta-thalassemia (Hbbth3/) to study their hypothesissingle-use EPO or knockout of a single Tfr2 allele can increase hemoglobin levels and RBCHowever, the absence of single allele genes with EPO or Tfr2 increased or did not improve spleen swelling in mice with beta-thalassemia, respectivelyto overcome this condition, the researchers speculated that a certain level of iron limit (by targeting Tmprss6) would improve spleen enlargement while retaining the beneficial effects on RBC mediated by EPO or Tfr2 deficiencyAlthough the monostatic anemia can also be improved with Tmprs6-ASO alone, hemoglobin levels increased significantly after the treatment of TheSs6-ASO or Tmprs6-ASO and Tfr2 single alleles, and the spleen swelling decreased significantlyin general, this study clearly suggests that these combination synths (Tmprs6-ASO,EPO or Tmprs6-ASO-Tfr2 single alleles) are superior to single treatments in alleviating IE and anemia of beta-thalassemia, and provide guidance for translating these combined methods into clinical applications